| KOWA CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120095043 | TRIGLYCERIDE-LOWERING AGENT AND HYPERINSULINISM-AMELIORATING AGENT - The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. | 04-19-2012 |
| 20120004306 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT - An external preparation containing the following components (A), (B), and (C):
| 01-05-2012 |
| 20120004305 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT - An external preparation containing the following components (A), (B), (C), and (D):
| 01-05-2012 |
| 20110319399 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT - An external preparation containing the following components (A) and (B):
| 12-29-2011 |
| 20110295189 | IONTOPHORETIC PREPARATION FOR TREATMENT OF BREAST CANCER AND/OR MASTITIS - The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential. | 12-01-2011 |
| 20110207742 | METHOD FOR REDUCTION, STABILIZATION AND PREVENTION OF RUPTURE OF LIPID RICH PLAQUE - There is to provide is an agent for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion comprising an effective amount of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-p yridyl]acetamide (hereinafter, referred to as compound 1), its pharmaceutically acceptable salt or a hydrate thereof and Pitavastatin, and a pharmaceutically acceptable carrier, wherein the agent is intended to be simultaneously administered, or separately administered with interval of time to a patient in need thereof There is also to provide a method for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion, comprising simultaneously administering, or separately administering with interval of time an effective amount of the compound 1, its pharmaceutically acceptable salt or a hydrate thereof and an effective amount of Pitavastatin to a patient in need thereof. | 08-25-2011 |
| 20110159058 | FILM PREPARATION CONTAINING LOPERAMIDE HYDROCHLORIDE - The film preparation of the present invention includes: a drug-containing intermediate layer containing loperamide hydrochloride, a terpene and a film-forming agent; and coating layers containing a film-forming agent and a plasticizer (but not a terpene) and laminated on both sides of the drug-containing intermediate layer. As a bitter taste derived from loperamide hydrochloride is thereby masked, uncomfortable sensation when taking the film preparation can be reduced. Furthermore, as this film preparation is rapidly dissolved (i.e., has a rapidly dissolving property) only with moisture in the oral cavity, it begins to work quickly and is very convenient when it is carried and taken. | 06-30-2011 |
| 20110015206 | METHOD OF STABILIZING LIPID-RICH PLAQUE AND METHOD OF PREVENTING RUPTURE THEREOF - A method of stabilizing lipid-rich plaques and method of preventing the rupture thereof, characterized in that an effective amount of 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, its acid adduct salt or a hydrate thereof is administered to patients with lipid-rich plaques. Prevention of plaque rupture and stabilization of plaques can be attained by reducing the occupancy of macrophages in lipid-rich plaques being unstable and tending to rupture among plaques being a lesion from a seat of atherosclerosis and simultaneously increasing the occupancy of collagen therein. | 01-20-2011 |
| 20100234599 | METHOD FOR PREPARING ACID ADDITION SALTS OF POLYACIDIC BASIC COMPOUNDS - This invention relates to a method for preparing an acid addition salt of a polyacidic basic compound, or a water adduct having basic site(s) stronger than pyridine. The method comprises reacting the polyacidic basic compound with an acid salt of pyridine. | 09-16-2010 |
| 20100234407 | PREVENTIVES/REMEDIES FOR MYELOMA TUMOR AND METHOD FOR DIAGNOSING THE SAME - The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory or inhibitory effect; as well as a diagnostic kit for a myeloma tumor, characterized by including a reagent for measuring blood osteopontin level, and a diagnostic method. | 09-16-2010 |
| 20100233287 | PREVENTING OR TREATING AGENT FOR GLAUCOMA - A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure. More specifically, a prophylactic or therapeutic agent for glaucoma, a preventing or treating agent for ocular hypertension, and eye drops containing (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl homopiperazine or its salt and phosphoric acid or its salt are provided. | 09-16-2010 |
| 20100209441 | DRUG FOR SUPPRESSING PATHOGEN OCCURRING IN VIVO - To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. | 08-19-2010 |
| 20100203542 | METHOD FOR TREATING AUTOIMMUNE DISEASES AND SCREENING METHOD FOR PREVENTIVE OR THERAPEUTIC AGENT FOR THE SAME - A screening method for a preventive or therapeutic agent for an autoimmune disease and/or for an apoptosis inhibitor, comprising determining retinoblastoma associated protein (RBAp48) production suppressing effect or RBAp48 production inhibitory effect of a sample. | 08-12-2010 |
| 20100197726 | INHIBITOR OF THE DIFFERENTIATION OF T CELLS INTO TH1 CELLS - The present invention is to provide an inhibitor that inhibits differentiation of T cells into Th1 cells. | 08-05-2010 |
| 20100184234 | REAGENT FOR MEASUREMENT OF CONCENTRATION OF LEAD, AND METHOD FOR MEASUREMENT OF CONCENTRATION OF LEAD - To provide a lead concentration determination reagent which realizes accurate, high-sensitivity, and simple-manner determination of the lead ion concentration (also referred to simply as “lead concentration”) of a sample solution in the presence of calcium ions, and a lead concentration determination method employing the reagent. | 07-22-2010 |
| 20100120732 | AGENT FOR PREVENTION AND/OR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - Provided is an agent for prevention and/or treatment of systemic lupus erythematosus, which comprises, in combination, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazine-3-one or a solvate thereof and a corticosteroid. The pharmaceutical agent of the present invention is orally administrable, has fewer adverse effects, exhibits an excellent effect of suppressing the symptoms associated with SLE, and thus is useful for prevention and treatment of SLE. | 05-13-2010 |
| 20100120712 | PHARMACEUTICAL COMPOSITION FOR MENIERE'S DISEASE - The present invention provides pharmaceutical composition for treating Meniere's disease, comprising saccharides or sugar alcohols as an active ingredient and polysaccharides, wherein the ratio by weight of the saccharides or sugar alcohols to the polysaccharides is about 100:2 to 100:50. The pharmaceutical composition of the present invention may eliminate the cathartic effect caused by saccharides or sugar alcohols to ensure the endolymphatic hydrops decompression effect. Therefore the effect of the therapeutic composition of the present invention is improved. The pharmaceutical composition may provide in gel, powder, granule form or the like. | 05-13-2010 |
| 20100086615 | AGENT FOR TREATMENT OF PULMONARY DISEASE - To provide a pulmonary disease therapeutic drug exhibiting high efficacy and reduced side effects. | 04-08-2010 |
| 20100075972 | AGENT FOR TREATMENT OF MULTIPLE SCLEROSIS - To provide a preventive and/or therapeutic drug for multiple sclerosis, which has high efficacy against multiple sclerosis, which exhibits excellent safety, and which can be orally administered. | 03-25-2010 |
| 20100016358 | GAMMA-GLOBIN INDUCER - The present invention is directed to a γ-globin inducer, to a prophylactic and/or therapeutic agent for sickle cell disease, and to a prophylactic and/or therapeutic agent for β-thalassemia, each containing, as an active ingredient, 4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]piperidine, a salt thereof, or a solvate of either of these. | 01-21-2010 |
| 20090317354 | Composition for restoring damaged skin comprising a saccaride and povidone-iodine - The present invention relates to a composition for repairing injured skin containing a saccharide and povidone-iodine. The present invention has the following characteristics: suppresses time-dependent increase of consistency, it is easy to use, it is a soft preparation, and has superior applicability to a deep wounded lesion and a granulation tissue. The composition of the present invention contains 50 to 90% by weight of saccharide, 0.5 to 10% by weight of povidone-iodine, 0.1 to 20% by weight of water and 0.01 to 10% by weight of phospholipid. | 12-24-2009 |
| 20090291980 | TRIGLYCERIDE-LOWERING AGENT AND HYPERINSULINISM-AMELIORATING AGENT - The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. | 11-26-2009 |
| 20090281106 | PROPHYLACTIC AND/OR THERAPEUTIC METHOD FOR RHEUMATOID ARTHRITIS - The present invention provides a prophylactic and/or therapeutic agent for rheumatoid arthritis comprising 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and leflunomide in combination. | 11-12-2009 |
| 20090281063 | IONTOPHORETIC PREPARATION FOR TREATMENT OF BREAST CANCER AND/OR MASTITIS - The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential. | 11-12-2009 |
| 20090275595 | METHOD FOR REDUCTION, STABILIZATION AND PREVENTION OF RUPTURE OF LIPID RICH PLAQUE - There is to provide is an agent for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion comprising an effective amount of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide (hereinafter, referred to as compound 1), its pharmaceutically acceptable salt or a hydrate thereof and Pitavastatin, and a pharmaceutically acceptable carrier, wherein the agent is intended to be simultaneously administered, or separately administered with interval of time to a patient in need thereof. There is also to provide a method for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion, comprising simultaneously administering, or separately administering with interval of time an effective amount of the compound 1, its pharmaceutically acceptable salt or a hydrate thereof and an effective amount of Pitavastatin to a patient in need thereof. | 11-05-2009 |
| 20090270399 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS - This invention relates to pyridazine derivatives represented by the formula (1): | 10-29-2009 |
| 20090263907 | REAGENT FOR LEAD CONCENTRATION DETERMINATION AND METHOD OF DETERMINING LEAD CONCENTRATION - To provide a lead concentration determination reagent which realizes accurate determination of the lead concentration of a sample solution in a simple manner with safety, even when the sample solution contains zinc ions, and a lead concentration determination method making use of the reagent. | 10-22-2009 |
| 20090209780 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXYBUTYRIC ESTER - To provide a process for producing an optically active 2-hydroxybutyric ester at high yield and high optical purity. | 08-20-2009 |
| 20090209765 | PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF - To provide an effective and simple process for producing 4-fluoroisoquinoline-5-sulfonyl halide or a salt thereof, and a simple method for separating for purification of the product from a by-produced position isomer thereof. | 08-20-2009 |
| 20090203701 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR RHEUMATOID ARTHRITIS - A medicament having excellent therapeutic and prophylactic effects on rheumatoid arthritis is provided. | 08-13-2009 |
| 20090186850 | PERITONEAL DIALYSIS METHOD - A peritoneal dialysate containing adenosine triphosphate or a salt thereof, and a peritoneal dialysis method using the dialysate. | 07-23-2009 |
| 20090143430 | ERYTHROPOIETIN PRODUCTION ACCELERATOR - The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1): | 06-04-2009 |
| 20090137657 | EXTERNAL LIQUID PREPARATION CONTAINING INDOMETHACIN - The present invention provides an indomethacin-containing external liquid preparation which provides good feeling of use, which exhibits high percutaneous absorption of indomethacin, and which, particularly in a low-temperature environment, does not cause precipitation of crystals with time. | 05-28-2009 |
| 20090131443 | METHOD FOR PREVENTION AND/OR TREATMENT OF RHEUMATOID ARTHRITIS - The invention provides a method for the prevention and/or treatment of rheumatoid arthritis, characterized in that the method comprises administering an IL-1β inhibitor and a calcineurin inhibitor, and a preventive and/or therapeutic medicine for rheumatoid arthritis including an IL-1β inhibitor and a calcineurin inhibitor in combination. | 05-21-2009 |
| 20090131330 | PAR-2 AGONIST - Disclosed is a compound represented by the following general formula (1): Ar—CO-AA | 05-21-2009 |
| 20090118299 | AGENT FOR PREVENTION OR TREATMENT OF GLAUCOMA - There is Provided an Agent for Prevention of glaucoma or an agent for prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. An agent for prevention or treatment of glaucoma comprising a Rho kinase inhibitor and a carbonic anhydrase inhibitor in combination. | 05-07-2009 |
| 20090082338 | PREVENTIVE OR REMEDY FOR GLAUCOMA - There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. A preventive or a remedy for glaucoma comprising a Rho kinase inhibitor and an α | 03-26-2009 |
| 20090076280 | PROCESSES FOR PRODUCTION OF OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUNDS AND INTERMEDIATES FOR PRODUCTION THEREOF - The invention provides a process for producing an optically active butyric acid compound and a production intermediate therefor at high yield and high purity. | 03-19-2009 |
| 20090069332 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS - This invention relates to pyridazine derivatives represented by the formula (1): | 03-12-2009 |
| 20090042901 | AGENT FOR PREVENTION/THERAPY OF DISEASE CAUSED BY KERATINOCYTE GROWTH - The present invention relates to an agent for the prevention/therapy of a disease caused by keratinocyte growth, which comprises, as an active ingredient, a compound represented by General Formula (1): | 02-12-2009 |
| 20090041843 | PHARMACEUTICAL PREPARATION HAVING EXCELLENT PHOTOSTABILITY - The present invention relates to a pharmaceutical preparation of high photostability which contains pitavastatin, which is an HMG-CoA reductase inhibitor, a salt of pitavastatin, or an ester of pitavastatin. The pharmaceutical preparation contains a pitavastatin compound, titanium oxide, and a colorant having a maximum absorption wavelength of 400 nm to 500 nm. | 02-12-2009 |
| 20090023944 | OPTICALLY ACTIVE PPAR-ACTIVATING COMPOUND INTERMEDIATE AND METHOD FOR PRODUCING SAME - The present invention provides a production intermediate for compound (A-1) and a method for producing the intermediate at high yield and high optical yield. | 01-22-2009 |
| 20090018121 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR RHEUMATOID ARTHRITIS - The present invention relates to a preventive and/or therapeutic agent for rheumatoid arthritis. The present invention provides a preventive and/or therapeutic agent for rheumatoid arthritis containing 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and a COX2 inhibitor. | 01-15-2009 |
| 20090005384 | Method for Producing Adsorptive Porous Body - The present invention relates to a method for producing a 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one adsorptive porous material characterized by treating a porous material with a halogen-containing organic solvent in which 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one is dissolved. The production method of the present invention is simple and easy, and the obtained adsorptive porous material is excellent in dissolution properties of 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one. | 01-01-2009 |
| 20080306102 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME - A Spiro oxindole compound represented by formula (1) of the present invention or salt thereof, or their solvate shows a superior inhibitory effect of 11β-hydroxysteroid dehydrogenasel, and is useful as an agent for preventing or treating a disease that involves 11β-hydroxysteroid dehydrogenasel (in particular, diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome). | 12-11-2008 |
| 20080299664 | Reagent For Lead Assay - A reagent for lead assay whereby a lead concentration can be accurately assayed even if an analyte contains calcium ions, and a method for assaying the lead concentration using the reagent for lead assay are provided. The reagent for lead assay contains a porphyrin nucleus-incorporated polymer, which is obtained by radical copolymerization of a porphyrin compound with a vinylene monomer, and calcium ions. | 12-04-2008 |
| 20080213776 | METHOD FOR TREATING AUTOIMMUNE DISEASES AND SCREENING METHOD FOR PREVENTIVE OR THERAPEUTIC AGENT FOR THE SAME - The present invention is directed to a method for treating autoimmune diseases comprising administering RBAp48 production suppressor or inhibitor; a screening method for a preventive or therapeutic agent for autoimmune diseases comprising determining RBAp48 production suppressing effect or inhibitory effect of a sample; a diagnosis agent or a diagnosing kit for autoimmune diseases containing a reagent for measuring RBAp48 level in gland tissue; and a diagnosis method for autoimmune diseases comprising measuring RBAp48 level in gland tissue. | 09-04-2008 |
